Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy

BACKGROUND: Infliximab trough level (ITL) severely affects therapeutic outcomes of Crohn’s disease (CD) patients under infliximab (IFX). Recently, frontier research has focused on identifying ITL based on different therapeutic targets. Although previous studies have elaborated clinical value of ITL...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Wan-Ting, Huang, Rong, Liu, Shan, Fan, Yi-Hong, Xu, Mao-Sheng, Xu, Yi, Ni, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254140/
https://www.ncbi.nlm.nih.gov/pubmed/35949356
http://dx.doi.org/10.3748/wjg.v28.i23.2582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254140/
https://www.ncbi.nlm.nih.gov/pubmed/35949356
http://dx.doi.org/10.3748/wjg.v28.i23.2582

Ejemplares similares